Precipio Inc (PRPO)
NASDAQ:PRPO
Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$23.09
$0.30(5.08%)
At close: 4:00 PM EST
$23.09
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$9.43 - $33.63
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$41.72M
Enterprise Value$42.61M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$3.49M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding1,787,372
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit3.77
Enterprise Value/Ebitda45.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Sustained Top-line GrowthConsistent >30% YoY revenue growth demonstrates durable demand for Precipio’s specialty diagnostic services and expanding clinical adoption. For a lab services model, sustained volume growth drives recurring billed activity, supports pricing negotiations with payors, and underpins long-term scalability as pipelines convert to revenue.
Positive Operating And Free Cash FlowThe shift to positive operating and free cash flow is a meaningful structural improvement versus prior years. Reliable cash generation reduces external financing need, funds commercial investment and validation activity, and provides a steadier base for executing growth without immediate capital raises if margins stabilize.
Significant Lab Capacity And ScalabilityHaving substantial unused lab capacity affords operational leverage: incremental test volume can flow through without major capex, improving margins as utilization rises. This structural scalability supports faster margin recovery and profitable growth as commercial pipeline converts to recurring orders.
Bears Say
Incomplete ProfitabilityDespite improving margins and positive cash flow, the company still posts a small net loss. Persistent negative net income constrains retained-capital accumulation and makes the firm more sensitive to reimbursement shocks or execution delays, limiting long-term strategic flexibility until profits are consistently positive.
Reimbursement And Margin PressureExposure to payor fee-schedule changes is a structural risk for diagnostics firms. The CMS cut produced an immediate revenue/gross profit hit; repeated or broader reimbursement reductions would compress margins, slow the path to sustained profitability, and require higher volumes or price adjustments to offset.
Customer Onboarding And Go-live Timing RiskOperational friction in onboarding (IT integration, validations, physician scheduling) creates durable execution risk: even a sizeable commercial pipeline can take months to convert. This timing variability slows revenue realization, reduces predictability of margin expansion, and can magnify the impact of reimbursement or staffing shocks.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $9.43 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $41.72M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Aug 04, 2026 which is in 66 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on May 14, 2026. The company reported -$0.809 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.809.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,787,372 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.809 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.951%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
-6.73%
Trailing 12-Months
Asset Growth
16.97%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong underlying trends and short-term headwinds. Positives include >30% YoY revenue growth, a growing pathology business, a $10M annualized commercial pipeline and positive operating cash flow. Near-term negatives included an 8% CMS reimbursement cut causing a ~$0.5M write-down, a QoQ gross margin decline (47% to 40%), and an adjusted EBITDA decline to -$200k driven by timing and investment-related factors. Management framed most negatives as one-time or investment-driven and emphasized scalability, available lab capacity, and commercial momentum, with expectations for margin recovery as product revenue scales.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
10.83% Insiders
2.28% Mutual Funds
1.91% Other Institutional Investors
83.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---